Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Bio-Rad Laboratories Q2 2024 Adj. EPS $3.11 Beats $2.01 Estimate, Sales $638.5M Miss $645.789M Estimate

Author: Benzinga Newsdesk | August 01, 2024 04:17pm
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $3.11 per share which beat the analyst consensus estimate of $2.01 by 54.73 percent. The company reported quarterly sales of $638.500 million which missed the analyst consensus estimate of $645.789 million by 1.13 percent. This is a 6.25 percent decrease over sales of $681.100 million the same period last year.

Posted In: BIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist